Key interactions of the mutant HIV-1 reverse transcriptase/efavirenz: an evidence obtained from ONIOM method

被引:13
|
作者
Boonsri, Pornthip [1 ,2 ,3 ]
Kuno, Mayuso [4 ]
Hannongbua, Supa [1 ,2 ,3 ]
机构
[1] Kasetsart Univ, Fac Sci, Dept Chem, Bangkok 10900, Thailand
[2] Kasetsart Univ, Ctr Nanotechnol KU, Bangkok 10900, Thailand
[3] Kasetsart Univ, NANOTEC Ctr Excellence, Bangkok 10900, Thailand
[4] Srinakharinwirot Univ, Fac Sci, Dept Chem, Bangkok 10110, Thailand
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; QUANTUM-CHEMICAL CALCULATIONS; WILD-TYPE; K103N MUTANT; CRYSTAL-STRUCTURES; EFAVIRENZ DMP-266; STRUCTURAL BASIS; DRUG-RESISTANCE; BINDING-ENERGY; HIGHLY POTENT;
D O I
10.1039/c1md00162k
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Two-layered ONIOM calculations were performed in order to compare the binding of efavirenz (EFV) to the HIV-1 RI binding pocket of both wild type (WT) and K103N enzymes. The K103N mutation reduces the binding affinity of the inhibitor by 5.81 kcal mol(-1) as obtained from the ONIOM2 (B3LYP/6-31G(d,p):PM3) method. These indicate that the loss of binding energy to K103N mutation can attribute to a weakened attractive interaction between the drug and residues surrounding in the binding pocket. The deformation of the K103N binding pocket requires more energy for structural rearrangement than that of the WT by approximately 4.0 kcal mol(-1). Moreover, the pairwise energies perfectly demonstrate that the K103N mutation affects on the loss of the interaction energy. In addition, the main influences are due to residues surrounding in the binding pocket; K101, K102, S105, V179, W229, P236 and E138. In particular, two residues; K101 and S105, established hydrogen bondings with the inhibitor. ONIOM calculations, resulting in the details of binding energy, interaction energy and deformation energy can be used to identify the key interaction and structural requirements of more potent HIV-1 RT inhibitor.
引用
收藏
页码:1181 / 1187
页数:7
相关论文
共 50 条
  • [1] Particular interaction between efavirenz and the HIV-1 reverse transcriptase binding site as explained by the ONIOM2 method
    Nunrium, P
    Kuno, M
    Saen-Oon, S
    Hannongbua, S
    CHEMICAL PHYSICS LETTERS, 2005, 405 (1-3) : 198 - 202
  • [2] Efavirenz Binding Site in HIV-1 Reverse Transcriptase Monomers
    Braz, Valerie A.
    Barkley, Mary D.
    Jockusch, Rebecca A.
    Wintrode, Patrick L.
    BIOCHEMISTRY, 2010, 49 (49) : 10565 - 10573
  • [3] Molecular Origins of HIV-1 reverse Transcriptase Resistance to Efavirenz
    Deredge, Daniel J.
    Howard, Kathryn J.
    Seckler, James M.
    Barkley, Mary D.
    Wintrode, Patrick L.
    BIOPHYSICAL JOURNAL, 2011, 100 (03) : 227 - 227
  • [4] Efavirenz Binding to HIV-1 Reverse Transcriptase Monomers and Dimers
    Braz, Valerie A.
    Holladay, Leslie A.
    Barkley, Mary D.
    BIOCHEMISTRY, 2010, 49 (03) : 601 - 610
  • [5] Effect of the NNRTI efavirenz on subunit assembly of HIV-1 reverse transcriptase
    Howard, KJ
    Ignatov, ME
    LeGrice, S
    Barkley, MD
    BIOPHYSICAL JOURNAL, 2003, 84 (02) : 171A - 171A
  • [6] Effects of efavirenz binding on the subunit equilibria of HIV-1 reverse transcriptase
    Venezia, CF
    Howard, KJ
    Ignatov, ME
    Holladay, LA
    Barkley, MD
    BIOCHEMISTRY, 2006, 45 (09) : 2779 - 2789
  • [7] Theoretical investigation on nevirapine and HIV-1 reverse transcriptase binding site interaction, based on ONIOM method
    Kuno, M
    Hannongbua, S
    Morokuma, K
    CHEMICAL PHYSICS LETTERS, 2003, 380 (3-4) : 456 - 463
  • [8] Efavirenz alters the interaction between HIV-1 reverse transcriptase and template/primer
    Radzio, J.
    Sheen, C.-W.
    Sluis-Cremer, N.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S133 - S133
  • [9] Synthesis and evaluation of analogs of Efavirenz (sustiva ™) as HIV-1 reverse transcriptase inhibitors
    Patel, M
    Ko, SS
    McHugh, RJ
    Markwalder, JA
    Srivastava, AS
    Cordova, BC
    Klabe, RM
    Erickson-Viitanen, S
    Trainor, GL
    Seitz, SP
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1999, 217 : U1206 - U1206
  • [10] Synthesis and evaluation of analogs of Efavirenz (SUSTIVA™) as HIV-1 reverse transcriptase inhibitors
    Patel, M
    Ko, SS
    McHugh, RJ
    Markwalder, JA
    Srivastava, AS
    Cordova, BC
    Klabe, RM
    Erickson-Viitanen, S
    Trainor, GL
    Seitz, SP
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (19) : 2805 - 2810